Author Correction: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

Journal article published in Nature medicine (2026) covering Survodutide.

Journal article.

The record

• Journal: Nature medicine
• Published: 2026-08-25
• PMID: 42642663 — DOI: 10.1038/s41591-026-04650-w
• Author countries: Canada, Germany, Ireland, UK, USA

Peptide profiles: Survodutide.

All indexed evidence: Survodutide trials & papers.

Related studies: Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell…, Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver…, Survodutide Once Weekly for the Treatment of Adults with Obesity, Survodutide for Obesity in Chinese Adults: Phase 3 Randomized Trial Design and Baseline….